The Prevalence and Concurrent Pathogenic Mutations of *KRAS*^{G12C} in Northeast Chinese Non-small-cell Lung Cancer Patients

This article was published in the following Dove Press journal:
Cancer Management and Research

Yan Liu¹
Hui Li¹
Jing Zhu²
Yang Zhang²
Xianhong Liu²
Rixin Li¹
Qiang Zhang³
Ying Cheng^{1,2}

¹Medical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, People's Republic of China; ²Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, 130012, People's Republic of China; ³Department of Bioinformatics, Burning Rock Biotech, Guangzhou, People's Republic of China

Objective: *KRAS* mutation is one of important driver genes in non-small-cell lung cancer (NSCLC) and the patients with *KRAS*^{G12C} mutations benefit from the inhibitor AMG510. However, the frequency, concurrent pathogenic mutations, and clinical characteristic of *KRAS*^{G12C} is unknown in the NSCLC population of Northeast China.

Methods: The retrospective analysis was derived from 431 NSCLC patients in Jilin Cancer Hospital between January 2018 and June 2019. The mutation frequency and concurrent mutations of *KRAS*^{G12C} in tumor or peripheral blood was detected by next-generation sequencing (NGS).

Results: The *RAS* mutant rate was observed in 10.7% (46/431) of this cohort. All *RAS*-driver cancers are caused by mutations in the *KRAS* isoform, while the *NRAS* and *HRAS* isoforms were not detected. Among *KRAS*-mutant patients, 42 (91.3%) showed exon 2 mutation in 12 codon and 13 codon. *KRAS*^{G12C} showed a 4.6% (20/431) mutation rate in this cohort and the highest frequency (43.5%, 20/46) in *KRAS*-mutant-positive patients. There was no difference between tumor tissue and plasma in terms of either *KRAS* or *KRAS*^{G12C} mutation. The most frequent co-occurrence mutations with *KRAS*^{G12C} were *TP53*, followed by *PTEN*. Furthermore, *KRAS*^{G12C} was exclusive with *STK11* mutation. *KRAS*^{G12C} mutation was associated with age, disease stage, and smoking status ($P=0.024$; $P=0.02$; $P=0.006$), smoking remained an independent factor for *KRAS*^{G12C} mutation ($P=0.037$), and higher mutation frequency in patients older than 60, stage I–III, or smoking in NSCLC ($P=0.0151$, $P=0.0343$, $P=0.0046$, respectively).

Conclusion: *KRAS* mutation was the only isoforms of *RAS* family, of these 43.5% harbored the *KRAS*^{G12C} subtype in northeastern Chinese NSCLC patients. *KRAS*^{G12C} is associated with age, pathological stage and smoking status, more commonly harbored *TP53/PTEN* mutations, and providing more genome profile for targeted therapy in local clinical practice.

Keywords: next-generation sequencing, non-small-cell lung cancer, *KRAS*^{G12C}, tissue, plasma, mutations

Introduction

Non-small-cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for 80–85% of lung cancers and has become the most fatal cancer in the world.¹ Recently, targeted therapy based on various driver oncogene variants (*EGFR*, *ALK* and *ROS1*, *KRAS*, *MET*, *PIK3CA*, *RET*, *BRAF*) has shown great antitumor activity; unfortunately, *KRAS* mutations had a more complicated mechanism in comparison with other driver genes such as *EGFR*, with poor prognosis and high risk of tumor recurrence.² Although prevalent, no specific treatment has been successfully developed for these NSCLCs.

Correspondence: Ying Cheng
Jilin Cancer Hospital, No. 1066 Jinhu Road, Chaoyang District, Changchun, Jilin Province, 130012, People's Republic of China
Tel +86 43185879901
Email chengying@csc.org.cn

KRAS mutations are some of the most prevalent alterations, approximately 10% of Asian NSCLC patients and 7.5% of Chinese NSCLC patients harbor the *KRAS* mutation, with codon 12 and 13 mutations being the most frequent and the most common subtypes are *G12C*, *G12V* and *G12D*.^{3,4} *KRAS*^{G12C} is a mutant type of *KRAS* guanosine triphosphatase (GTPase), and an inhibitor targeting *KRAS*^{G12C} is a promising novel tumor-specific therapy for tumors driven by mutant proteins.⁵ Current studies on *KRAS*^{G12C} inhibitors and the mechanism of drug resistance have confirmed that patients with *KRAS*^{G12C} mutations benefit from the inhibitor AMG510,⁶ which has also been approved by the FDA as an orphan drug for NSCLC and colon cancer with *KRAS*^{G12C} mutation. *KRAS*^{G12C} can induce allosteric switch II pocket (s-iip) and take cys-12 as the specific covalent target of alleles, which were considered as potential drug targets.² Now, *KRAS*^{G12C} mutation was verified by the NGS, various clinical parameters and genetic mutation have been proposed to predict the relevance with *KRAS*^{G12C} (such as sex, age, smoking, co-mutation gene). In the current study we aim to discover a more precise delineation of candidate target populations and distinctive *KRAS*^{G12C} co-mutation subtypes in the northeast Chinese population. We retrospectively investigated and evaluated the *KRAS*^{G12C} mutation in northeast Chinese NSCLC, and the association between clinical factors and *KRAS*^{G12C} mutation status.

Materials and Methods

Patients and Samples

Four hundred and thirty-one samples were collected from Jilin Cancer Hospital between January 2018 and June 2019, 268 cases were tested through eight gene panel, 81 cases by 168 gene panel and 82 matched cases using 520 gene panel, respectively (Figure 1). Clinic pathological data were collected from the electronic medical records in Jilin Cancer Hospital, and the factors included age, sex, and clinical stage, smoking history, brain metastasis, PS score and histology. All participants signed the informed consent agreement before participating in the study, the data were anonymized, the study was approved by the Clinical Research Ethics Committee of Jilin Cancer Hospital and was conducted in accordance with the Declaration of Helsinki.

DNA Extraction

DNA was extracted by DNA FFPE tissue kit (AmoyDx, China) and ctDNA extraction kit (QIAGEN, Germany)

Figure 1 Study flowchart.

Abbreviations: NSCLC, non-small-cell lung cancer; NGS, next-generation sequencing.

according to the manufacturer's instructions. DNA concentration was quantified by Nanodrop 3000C and Qubit 4.0 (Thermo Fisher Scientific, Waltham, MA, USA).

Next-generation Sequencing Analysis

Library preparation was performed following manufacturer's protocol (Burning Rock Biotech, Guangzhou, China). DNA Fragments (range: 200–400 bp) were purified by AMPure beads (Beckman Coulter, CA, USA), and captured with probe baits, hybrid selection with magnetic beads by RT-PCR amplification. Subsequently, DNA quality and size were assessed by high-sensitivity DNA assay. Indexed samples were sequenced on a MiSeq system (Beckman Coulter) with paired-end reads. The input of extracted DNA should be in the range of (30–200 ng). Sequencing platform was used by Illumina NextSeq 500 Sequencing Platform with tissue DNA (1000X) and cfDNA (20000X). All samples were analyzed by NGS targeted panel (Burning Rock Dx, China), which eight-gene panel covers well-known lung adenocarcinoma driver genes, 168 genes covers known lung cancer-related genes and 520 genes covers solid tumor-related genes. (Supplemental Table 1).

Statistical Analysis

All data was performed by SPSS Statistics 19.0 software (IBM Corporation, Armonk, NY, USA). Fisher's exact test was used to evaluate mutation differences and clinical factor between *KRAS*^{G12C} and *KRAS*^{wt}. Logistic regression analysis was used

to identify as independent factors for $KRAS^{G12C}$ mutations. A P -value of <0.05 was considered statistically significant.

Results

Patient Population

Among 431 samples were those from tumor tissue 332 (77.04%), 99 (22.96%) plasma; 198 women (54.07%) and 233 men (45.93%), with a median age of 63 years (range: 34–86 years), respectively. Of the 431 patients, 263 (61.02%) were smokers, and 168 were nonsmokers. The histological characterization of tumors revealed that 370 samples were adenocarcinoma (85.85%), 61 were squamous cell carcinoma (14.15%). Of the 431 patients, characterization of the pathological stage showed 115 samples in stage I–III (26.68%), and 316 samples in stage IV (73.32%) (Table 1).

$KRAS^{G12C}$ is the Most Common Mutation Type of $KRAS$ in NSCLC

The RAS mutation rate was 10.7% (46/431), and $KRAS$ was the only mutation subtype of RAS ($NRAS$, $KRAS$, $HRAS$). 42 (91.3%) indicated $KRAS$ gene exon 2 mutation, 12 and 13 codon of $KRAS$ gene mutations were detected, and $KRAS^{G12C}$ showed the highest frequency, the total mutation rate of $KRAS^{G12C}$ in NSCLC was 4.6% (20/

Figure 2 Mutation frequencies of $KRAS$ subtypes.

431) and 43.5% (20/46) of $KRAS$ mutant subtypes, followed by 17.4% (8/46) of $KRAS^{G12D}$, 8.7% (4/46) of $KRAS^{G12V}$, and 8.7% (4/46) of $KRAS^{G12A}$. The mutation frequency of other $KRAS$ types was lower (Figure 2).

$KRAS^{G12C}$ Mutation Between Tumor Tissue and Plasma

We compared the $KRAS$ mutation spectrums between tumor tissue and ctDNA derived from peripheral blood in this study. Collectively, 37 (11.14%) and 16 (4.81%) patients had $KRAS$ and $KRAS^{G12C}$ mutation spectrum in tumor tissue, nine (9.09%) and four (4.04%) patients in ctDNA, but no significant difference was found in the two sample types ($P=0.711$, $P=1.000$, Table 2), respectively.

Co-occurring Genomic Alterations Between $KRAS^{G12C}$ and Lung Cancer Pathogenic Gene

Lung cancer driver genes (include $EGFR$, RAS , ALK , $ROS1$, MET , RET , $BRAF$, and $HER-2$) mutation samples were observed in 332 (77.3%) of 431 patients. Eight (40%) of 20 patients harbored only $KRAS^{G12C}$

Table 1 Patient Characteristics

Characteristics	n (%)
Age (years)	63 (34–86)
Sex	
Male	198 (45.93)
Female	233 (54.07)
Stage	
I–III	115 (26.68)
IV	316 (73.32)
Smoking history	
Yes	168 (38.98)
No	263 (61.02)
Brain metastasis	
Yes	106 (24.59)
No	325 (75.41)
PS score	
0–I	365 (84.68)
2–3	66 (15.32)
Histology	
Adenocarcinoma	370 (85.85)
Squamous cell carcinoma	61 (14.15)

Table 2 Mutation Frequencies of $KRAS$ Subtypes Between Tumor Tissue and Plasma

Sample Type	$KRAS$		P	$KRAS^{G12C}$		P
	mut	wt		mut	wt	
Tumor tissue	37	295	0.711	16	316	1.000
Plasma	9	90		4	95	
Total	46	385		20	411	

mutations, and 12 (60%) had multiple *KRAS*^{G12C} mutations, including eight (40%) *KRAS*^{G12C} patients had co-occurring driver oncogenes, was higher trend than *KRAS*^{other} with driver oncogenes mutations (6/26,23%), but no statistical significance ($P=0.33$), the most commonly co-occurring genomic alterations with *KRAS*^{G12C} were *EGFR* (10%, 2/20), *ROS1* (10%, 2/20), *MET*

(10%), *HER2* (5%, 1/20), *ALK* (5%, 1/20), *BRAF* (5%, 1/20), and *RET* (0%), respectively (Figure 3, Supplemental Table 2). One hundred and sixty-three patients from 168 gene panel or 520 gene panel found that the *KRAS*^{G12C} gene is often accompanied by *TP53* and *PTEN* mutation, the mutation rates were 50% (3/6) and 16.7% (1/6), respectively, but *STK11* (0.0%, 0/6).

Figure 3 Driver genetic mutations spectrums identified by next-generation sequencing of 332 patients with NSCLC tumor tissue and plasma. Side bar represents the percentage of patients with driver gene mutation. Top bar represents the number of mutations per patient. Different types of mutations are denoted in different colors.

Age, Smoking History and Pathological Stage Associated with $KRAS^{G12C}$ Mutation

The mutation rate of $KRAS^{G12C}$ gene in smokers was higher than that in nonsmokers, 8.33% (14/168) vs 2.28% (6/263), $P=0.0046$). $KRAS^{G12C}$ has a higher mutation rate in age (≥ 60 years) 15.2% (18/274) vs 1.27% (2/157); $P=0.0151$). $KRAS^{G12C}$ mutation was associated with the pathological staging of the patients, 8.69% (10/115) vs 3.16% (10/316), $P=0.0343$), but was not associated with gender, brain metastasis, PS score, and histology ($P=0.2515$, $P=0.4282$, $P=0.5266$ and $P=0.7526$) (Table 3), to further identify the values of clinical factor on $KRAS^{G12C}$ mutations, logistic regression analysis was included. In the univariate logistic analysis, age, smoker, clinical stage were identified as independent factors for $KRAS^{G12C}$ mutations (OR=0.551, $P=0.024$; OR=5.449, $P=0.02$; OR=0.343, $P=0.006$). In the multivariate logistic model, smoker (OR=0.306, $P=0.037$) remained independent factors for $KRAS^{G12C}$ (Table 4).

Table 3 431 Correlation Analysis Between $KRAS^{G12C}$ and Clinic Pathological Factors in Patients

	$KRAS^{G12C}$ - mut n=20	$KRAS^{G12C}$ -wt n=411	P-value
Sex			
Male	12	186	0.2515
Female	8	225	
Age			
<60 year	2	155	0.0151*
≥ 60 year	18	256	
Stage			
I–III	10	105	0.0343*
IV	10	306	
Smoking history			
Yes	14	154	0.0046**
No	6	257	
Brain metastasis			
Yes	3	103	0.4282
No	17	308	
PS score			
0–I	16	349	0.5266
2–3	4	62	
Histology			
Adenocarcinoma	18	352	0.7526
Squamous cell carcinoma	2	59	

Notes: * P -value <0.05; ** P -value <0.01.

Abbreviations: mut, mutation; wt, wild type.

Furthermore, we found that $KRAS^{G12C}$ was dominant in male smokers (100%, 4/4)

Discussion

Previously reported RAS was detected in about 25–30% of tumors, several studies consistently reported that Westerners have a higher mutation rate than Asians (26% vs 11%).⁷ Another report similarly indicated 30% of RAS mutations in Western patients and 5–15% in the Asian population,⁸ which accounts for about 86% $KRAS$, 11% $NRAS$ and 3% $HRAS$ mutation of RAS -induced NSCLC, $KRAS$ accounts for 90% of RAS gene mutations in lung adenocarcinoma and is the most common oncogene in NSCLC.⁹ Our data are consistent with recent studies, our results might indicate the current view that $KRAS$ was the only RAS -mutant isoform, the mutation rate was 10.7% in 431 NSCLC patients, similar to the rates reported by Jia's group and Liu's group.^{10,11} Further studies showed that the $KRAS^{G12C}$ mutation rate is 4.6% in lung cancer, and 43.5% in $KRAS$ mutation for our study. It was similar to several studies in that the $KRAS^{G12C}$ mutation frequency range is from 35% to 45% followed by $KRAS^{G12V}$ and $KRAS^{G12D}$ in $KRAS$ mutant lung cancer, but a lower frequency reported by Liu's group.^{9,11–15} One key finding of our study was that $KRAS$, including $KRAS^{G12C}$ mutation of NSCLC reflected no difference in tissue and blood. Furthermore, this study also reveals the widespread existence of concomitant mutations in patients with $KRAS^{G12C}$ mutant advanced NSCLC, especially driver gene mutations. The three predominant $KRAS$ co-mutations were detected including $EGFR$ - $KRAS^{G12C}$ (10%), equal to $ROS1$ - $KRAS^{G12C}$ (10%) and MET - $KRAS^{G12C}$ (10%). We found the four cases with $EGFR$ - $KRAS$ concomitant mutations in our cohort were all tested before $EGFR$ -TKI treatment, thus partly ruling out the possibility that $EGFR$ - $KRAS$ co-mutation was related to $EGFR$ -TKI resistance.¹⁶ Unfortunately, neither were the four cases derived from two separate tumor tissue. The incidence rate of $EGFR$ - $KRAS$ in the Chinese cohort might be likely ethnic-unique, based on the knowledge that the prevalence of $EGFR$ mutation is higher in the Asian population.¹⁷ The co-occurrence of $EGFR$ and $KRAS$ was 0.92% (4/431) in our study, which was supported by Scheffler et al¹³ (1.2%). The four concomitant mutations were $KRAS^{G12C}$ (n=2) co-occurring with either $EGFR$ V1097I (n=1) or $EGFR$ amplification (n=1) and $KRAS^{G12C}$ (n=2) co-occurring with $EGFR$ 19del (n=2). Although previous studies had reported that $KRAS$ are mutually exclusive with mutations in $EGFR$ and ALK in NSCLC,^{18,19} but coexisting $EGFR$ and $KRAS$ mutations have also been reported.^{20,21} (Zhu et al reported that three

Table 4 Univariate and Multivariate Analysis of *KRAS*^{G12C} and Clinical Factor

		Univariate Analysis			Multivariate Analysis		
		OR	95%CI	P-value	OR	95%CI	P-value
Sex	Male	1		0.202	1		0.936
	Female	0.551	0.221–1.377		1.044	0.363–3.001	
Age	<60	1		0.024	1		0.076
	≥60	5.449	1.247–23.805		3.932	0.868–17.823	
Stage	I–III	1		0.02	1		0.082
	IV	0.343	0.139–0.847		0.415	0.154–1.118	
Smoking history	Yes	1		0.006	1		0.037
	No	0.257	0.097–0.682		0.306	0.101–0.929	
Brain metastasis	Yes	1		0.315	1		0.871
	No	1.895	0.544–6.598		0.892	0.226–3.516	
PS score	0–1	1		0.553	1		0.704
	2–3	1.407	0.455–4.350		1.256	0.388–4.066	
Histology	Adenocarcinoma	1		0.588	1		0.617
	Squamous cell carcinoma	0.663	0.15–2.932		0.677	0.147–3.116	

patients with coexisting *EGFR* and *KRAS* mutations were found in 206 patients (1.4%).²² We infer that genetic mutation status could be related with different races, sample numbers, as well as test methodology. Nevertheless, current data about *KRAS* co-occurring mutations in lung cancer is insufficient. Co-occurrence with *TP53* or *STK11* mutations is common in *KRAS* mutations.^{23,24} *KRAS* and *TP53* co-mutations indicated that tumors harboring those mutations could be more responsive to immune checkpoint inhibition in lung cancer.²⁵ Conversely, tumors harboring concurrent *KRAS* and *STK11* mutations could be associated with an immunosuppressive microenvironment.^{26,27} Furthermore, the absence of *PTEN* promotes resistance to T cell-mediated immunotherapy.²⁸ So we evaluated the mutation status of *TP53*, *STK11* or *PTEN* in *KRAS*^{G12C} mutant patients, and it indicated that in the landscape of concurrent genetic alterations in patients with *KRAS*^{G12C}, the co-mutation rates were 50% and 16.7%, but *KRAS*^{G12C} was exclusive with *STK11* mutation.

KRAS^{G12C} (c.34G>T) alteration is a transversion and *KRAS* transversion mutations (G→T or G→C) were more

common in smokers, in contrast, transition mutations (G→A) were more common in never-smokers in lung adenocarcinomas (n=500).²⁹ Our data showed that smokers more commonly harbored *KRAS*^{G12C} mutations than *KRAS*^{wt} (70% vs 37.5%), which is consistent with reports by Liu et al and Dogan et al.^{11,30} Data showed that *KRAS*-mutant NSCLC is genetically complex, with a higher frequency of co-occurring mutations with *TP53*, *STK11*, *MET* and *ERBB2* amplifications,²⁹ however, no conclusions implied that the co-occurrence mutations were related to the transversion. In comparison to *KRAS*^{other}, *KRAS*^{G12C} showed higher mutation frequency in patients older than 60 years, and stage I–III. Our findings were supported by other studies.^{11,13,31}

In summary, our study indicated that *KRAS*^{G12C} mutations were the most frequent mutant subtype of *KRAS* in northeast Chinese NSCLC patients and might be involved in the smoking, age, and clinical stage, especially we demonstrated a high frequency of *KRAS*^{G12C} concomitant *TP53/PTEN/EGFR*. In addition, no difference was observed between tissue and plasma in the *KRAS*^{G12C}

subgroup of the northeast Chinese NSCLC patients. Our findings might contribute to distinct therapeutic guidance in NSCLC. More data should be collected and explored to address predictive and prognostic value of *KRAS*^{G12C} in future studies.

Acknowledgments

This research was supported by Scientific Research Project of Jilin Provincial Health and Family Planning Commission (grant numbers 2018Q007, 2019J077); Science and Technology Agency of Jilin Provincial Project (grant numbers 20200201518JC, 202002063JC); Special Project for Significant New Drug Research and Development in the Major National Science and Technology Projects of China (grant numbers 2020ZX09201-024).

Disclosure

Qiang Zhang is an employee of Burning Rock Biotech. The authors report no other potential conflicts of interests in this work.

References

- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115–132. doi:10.3322/caac.21338
- Janes MR, Zhang J, Li LS, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. *Cell*. 2018;172:578–589. e17. doi:10.1016/j.cell.2018.01.006
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014;511(7511):543–550. doi:10.1038/nature13385
- Zhuang X, Zhao C, Li J, et al. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. *Cancer Med*. 2019;8(6):2858–2866. doi:10.1002/cam4.2183
- Lou K, Steri V, Ge AY, et al. KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies. *Sci Signal*. 2019;12(583):eaaw9450. doi:10.1126/scisignal.aaw9450
- Lanman BA, Allen JR, Allen JG, et al. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. *J Med Chem*. 2020;63:52–65. doi:10.1021/acs.jmedchem.9b01180
- Ricciuti B, Leonardi GC, Metro G, et al. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. *Expert Rev Respir Med*. 2016;10(1):53–68. doi:10.1586/17476348.2016.1115349
- Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. *Nat Rev Cancer*. 2011;11:761–774.
- Ni D, Li X, He X, Zhang H, Zhang J, Lu S. Drugging K-RasG12C through covalent inhibitors: mission possible? *Pharmacol Ther*. 2019;202:1–17. doi:10.1016/j.pharmthera.2019.06.007
- Jia Y, Jiang T, Li X, et al. Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer. *Oncol Lett*. 2017;14:6525–6532. doi:10.3892/ol.2017.7016
- Liu SY, Sun H, Zhou JY, et al. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. *Biomark Res*. 2020;8:22. doi:10.1186/s40364-020-00199-z
- Aredo JV, Padda SK, Kunder CA, et al. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. *Lung Cancer*. 2019;133:144–150. doi:10.1016/j.lungcan.2019.05.015
- Scheffler M, Ihle MA, Hein R, et al. K-ras mutation subtypes in NSCLC and associated co-occurring mutations in other oncogenic pathways. *J Thorac Oncol*. 2019;14(4):606–616. doi:10.1016/j.jtho.2018.12.013
- Izar B, Zhou H, Heist RS, et al. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. *J Thorac Oncol*. 2014;9(9):1363–1369. doi:10.1097/JTO.0000000000000266
- Nadal E, Chen G, Prensner JR, et al. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. *J Thorac Oncol*. 2014;9(10):1513–1522. doi:10.1097/JTO.0000000000000305
- Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. *Clin Cancer Res*. 2016;22(19):4837–4847. doi:10.1158/1078-0432.CCR-15-1915
- Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol*. 2005;23(11):2493–2501. doi:10.1200/JCO.2005.01.388
- Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR and KRAS in non-small cell lung cancer. *Clin Cancer Res*. 2013;19(15):4273–4281. doi:10.1158/1078-0432.CCR-13-0318
- Unni AM, Lockwood WW, Zejnullahu K, et al. that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. *Elife*. 2015;4(4):e06907. doi:10.7554/eLife.06907
- Gumerlock PH, Holland WS, Chen H, et al. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib. *J Clin Oncol*. 2005;23:623s. doi:10.1200/jco.2005.23.16_suppl.7008
- Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. *Clin Cancer Res*. 2006;12:2538–2544. doi:10.1158/1078-0432.CCR-05-2845
- Zhu CQ, Sants GC, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer institute of Canada Clinical Trial Group study BR.21. *J Clin Oncol*. 2008;26(26):4268–4275. doi:10.1200/JCO.2007.14.8924
- Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol*. 2011;12:175e180.
- Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature*. 2008;455(7216):1069e1075. doi:10.1038/nature07423
- Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. *Clin Cancer Res*. 2017;23(12):3012–3024. doi:10.1158/1078-0432.CCR-16-2554
- Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. *Cancer Discov*. 2018;8:822–835. doi:10.1158/2159-8290.CD-18-0099
- Schabath MB, Welsh EA, Fulp WJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. *Oncogene*. 2016;35(24):3209–3216. doi:10.1038/onc.2015.375
- Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. *Cancer Discov*. 2016;6:202–216. doi:10.1158/2159-8290.CD-15-0283

29. El Osta B, Behera M, Kim S, et al. Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience. *J Thorac Oncol*. 2019;14(5):876–889. doi:10.1016/j.jtho.2019.01.020
30. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. *Clin Cancer Res*. 2012;18:6169–6177. doi:10.1158/1078-0432.CCR-11-3265
31. Arbour KC, Jordan E, Kim HR, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. *Clin Cancer Res*. 2018;24:334–340. doi:10.1158/1078-0432.CCR-17-1841

Cancer Management and Research

Dovepress

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>